ARe we there yet? Understanding androgen receptor signaling in breast cancer
The role of androgen receptor (AR) activation and expression is well understood in prostate
cancer. In breast cancer, expression and activation of AR is increasingly recognized for its …
cancer. In breast cancer, expression and activation of AR is increasingly recognized for its …
Androgen receptor as an emerging feasible biomarker for breast cancer
CP You, MH Leung, WC Tsang, US Khoo, H Tsoi - Biomolecules, 2022 - mdpi.com
Biomarkers can be used for diagnosis, prognosis, and prediction in targeted therapy. The
estrogen receptor α (ERα) and human epidermal growth factor receptor 2 (HER2) are …
estrogen receptor α (ERα) and human epidermal growth factor receptor 2 (HER2) are …
[HTML][HTML] Consideration of breast cancer subtype in targeting the androgen receptor
CM Venema, RD Bense, TG Steenbruggen… - Pharmacology & …, 2019 - Elsevier
The androgen receptor (AR) is a drug target in breast cancer, and AR-targeted therapies
have induced tumor responses in breast cancer patients. In this review, we summarized the …
have induced tumor responses in breast cancer patients. In this review, we summarized the …
Targeting the androgen receptor in breast cancer
The androgen receptor (AR) is expressed in the majority of breast cancer and across the
three main breast cancer subtypes. Historically, the oncogenic role of AR has best been …
three main breast cancer subtypes. Historically, the oncogenic role of AR has best been …
Androgen receptor in breast cancer: The “5W” questions
S Ravaioli, R Maltoni, B Pasculli, P Parrella… - Frontiers in …, 2022 - frontiersin.org
Androgen receptor (AR) is expressed in 60-70% of breast cancers (BCs) and the availability
of anti-AR compounds, currently used for treating prostate cancer, paves the way to tackle …
of anti-AR compounds, currently used for treating prostate cancer, paves the way to tackle …
[HTML][HTML] Potential novel therapy targets in neuroendocrine carcinomas of the breast
S Vranic, J Palazzo, S Sanati, E Florento… - Clinical breast …, 2019 - Elsevier
Introduction Neuroendocrine carcinoma (NEC) of the breast is a rare, special type of breast
cancer, reportedly constituting 2% to 5% of all breast cancers. Although breast NEC does …
cancer, reportedly constituting 2% to 5% of all breast cancers. Although breast NEC does …
Phase II trial of fulvestrant plus enzalutamide in ER+/HER2− advanced breast cancer
AD Elias, NS Spoelstra, AW Staley, S Sams… - NPJ Breast …, 2023 - nature.com
This clinical trial combined fulvestrant with the anti-androgen enzalutamide in women with
metastatic ER+/HER2− breast cancer (BC). Eligible patients were women with ECOG 0–2 …
metastatic ER+/HER2− breast cancer (BC). Eligible patients were women with ECOG 0–2 …
Modulating the activity of androgen receptor for treating breast cancer
CP You, H Tsoi, EPS Man, MH Leung… - International Journal of …, 2022 - mdpi.com
The androgen receptor (AR) is a steroid hormone receptor widely detected in breast cancer.
Evidence suggests that the AR might be a tumor suppressor in estrogen receptor alpha …
Evidence suggests that the AR might be a tumor suppressor in estrogen receptor alpha …
Hormonal modulation of ESR1 mutant metastasis
Estrogen receptor alpha gene (ESR1) mutations occur frequently in ER-positive metastatic
breast cancer, and confer clinical resistance to aromatase inhibitors. Expression of the ESR1 …
breast cancer, and confer clinical resistance to aromatase inhibitors. Expression of the ESR1 …
Revisiting androgen receptor signaling in breast cancer
Aberrant estrogen receptor (ER) signaling is central to the pathogenesis of many breast
cancers. Like ER, the androgen receptor (AR) is a steroid nuclear receptor that is frequently …
cancers. Like ER, the androgen receptor (AR) is a steroid nuclear receptor that is frequently …